Marrow suppression with myelodysplastic features, hypoerythropoetinemia, and lipotrophic proptosis due to rosiglitazone.

Mark Lucarelli // Publications // Dec 01 2009

PubMed ID: 20131689

Author(s): Clevidence DE, Juckett MB, Lucarelli MJ. Marrow suppression with myelodysplastic features, hypoerythropoetinemia, and lipotrophic proptosis due to rosiglitazone. WMJ. 2009 Dec;108(9):462-5. PMID 20131689

Journal: Wmj : Official Publication Of The State Medical Society Of Wisconsin, Volume 108, Issue 9, Dec 2009

Thiazolidinediones (TZDs) are frequently used pharmacotherapeutics for type II diabetes mellitus, which exert their effect through peroxisomal proliferator agonist receptor (PPAR) mediated increased insulin sensitivity. TZDs are known to cause marrow suppression and to stimulate adipogenesis. Case and cohort studies show TZDs worsen thyroid-associated orbitopathy. We present a case consistent with earlier reports of marrow suppressive pancytopenia manifesting as myelodysplastic syndrome, a new implication of hypoerythropoetinemia, and non-Graves’-associated proliferative proptosis.